Skip to main content
Premium Trial:

Request an Annual Quote

Bioarray PGS+PGD Single Biopsy Kit

Bioarray has launched its PGS+PGD Single Biopsy kit which screens aneuploidies and identifies embryos with pathological mutation from a single biopsy sample. The kit uses next-generation sequencing technology and bioinformatics analysis to determine whether an embryo carries aneuploidies, such as trisomy of chromosome 21, and allow for users to reject embryos affected by the mutation and/or select those not affected. Users can expect results to be processed within three to five days.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.